Vascular Biogenics Ltd. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in developing some of their medical products.
“The present invention is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis”
“VB-111 is an innovative, targeted anti-angiogenic agent that has shown efficacy results in clinical trials of three different cancer indications, as well as robust data in various animal models, including thyroid cancer. Together, we believe these data suggest that VB-111 may be an effective cancer therapy with a broad therapeutic potential,” said Yael Cohen, MD, VP Clinical Development at VBL.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. [Source: Reuters]
Company Website: http://www.vblrx.com